# Centogene N.V. (CNTG)

Source: https://www.quantisnow.com/company/CNTG
Generated: 2026-11-04T03:14:41.447Z

- Ticker: CNTG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical Specialities
- IPO year: 2019
- Website: centogene.com

## About

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

## Latest CNTG news and filings

- 2025-03-12 10:30 UTC [CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners](https://www.quantisnow.com/insight/centogene-closes-strategic-transaction-with-private-equity-group-charme-capital-5939732)
- 2024-12-05 00:51 UTC [CENTOGENE Announces Voting Results of Extraordinary General Meeting](https://www.quantisnow.com/insight/centogene-announces-voting-results-of-extraordinary-general-meeting-5800999)
- 2024-11-13 11:30 UTC [CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners](https://www.quantisnow.com/insight/centogene-signs-strategic-transaction-with-private-equity-group-charme-capital-5769738)
- 2024-09-25 12:00 UTC [CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology](https://www.quantisnow.com/insight/centogene-data-on-novel-genetic-risk-factor-for-parkinsons-disease-5704188)
- 2024-08-19 23:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5665527)
- 2024-08-07 22:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5648680)
- 2024-08-07 22:19 UTC [CENTOGENE Receives Delisting Notice From Nasdaq](https://www.quantisnow.com/insight/centogene-receives-delisting-notice-from-nasdaq-5648527)
- 2024-08-01 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5638423)
- 2024-08-01 20:15 UTC [CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors](https://www.quantisnow.com/insight/centogene-publication-in-brain-journal-reveals-15-of-parkinsons-disease-5638393)
- 2024-06-20 12:17 UTC [Market Chatter] [Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.](https://www.quantisnow.com/insight/centogene-shares-are-trading-higher-after-the-company-signed-a-5567301)
- 2024-06-20 12:12 UTC [Market Chatter] [Centogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development](https://www.quantisnow.com/insight/centogene-and-c-path-sign-mou-for-collaboration-in-lysosomal-disease-5567281)
- 2024-06-20 12:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5567217)
- 2024-06-20 12:00 UTC [C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development](https://www.quantisnow.com/insight/c-path-and-centogene-mou-to-enhance-collaboration-in-lysosomal-disease-5567191)
- 2024-05-31 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5529834)
- 2024-05-31 20:30 UTC [CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting](https://www.quantisnow.com/insight/centogene-announces-adoption-of-all-resolutions-tabled-at-2024-annual-5529789)
- 2024-05-29 11:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5521751)
- 2024-05-17 11:20 UTC [SEC Form IRANNOTICE filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-irannotice-filed-by-centogene-nv-5498839)
- 2024-05-16 12:18 UTC [Market Chatter] [Centogene shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.](https://www.quantisnow.com/insight/centogene-shares-are-trading-higher-after-the-company-reported-a-5495690)
- 2024-05-15 21:20 UTC [Market Chatter] [CENTOGENE FY23 EPS €(1.27) Vs €(1.19); Revenue €48.5 Million Up From €47.5 Million YoY;](https://www.quantisnow.com/insight/centogene-fy23-eps-127-vs-119-revenue-485-million-up-5494533)
- 2024-05-15 21:17 UTC [CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/centogene-reports-full-year-2023-financial-results-and-recent-business-5494511)
- 2024-05-15 21:12 UTC [SEC Form 20-F filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-centogene-nv-5494480)
- 2024-05-15 21:11 UTC [Market Chatter] [CENTOGENE Entered Into Agrements With Lifera; Provides ~$20M Funding](https://www.quantisnow.com/insight/centogene-entered-into-agrements-with-lifera-provides-20m-funding-5494451)
- 2024-05-15 21:10 UTC [CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position](https://www.quantisnow.com/insight/centogene-secures-approx-20-million-to-strengthen-cash-position-5494438)
- 2024-05-15 21:07 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5494420)
- 2024-05-15 20:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5494270)
- 2024-05-14 12:53 UTC [Market Chatter] [CENTOGENE And Evotec Announce Discovery Of New Molecule To Treat Gaucher Disease](https://www.quantisnow.com/insight/centogene-and-evotec-announce-discovery-of-new-molecule-to-treat-5487704)
- 2024-05-14 12:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5487609)
- 2024-05-14 12:30 UTC [CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease](https://www.quantisnow.com/insight/centogene-and-evotec-discover-promising-new-molecule-to-treat-gaucher-5487607)
- 2024-05-10 10:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5479778)
- 2024-05-10 10:30 UTC [CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients](https://www.quantisnow.com/insight/centogene-biodatabank-grows-to-incorporate-disease-insights-from-over-850000-5479777)
- 2024-05-01 20:24 UTC [SEC Form NT 20-F filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-nt-20-f-filed-by-centogene-nv-5449947)
- 2024-05-01 20:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5449940)
- 2024-04-19 09:45 UTC [Market Insight] [Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-wang-lee-group-shares-are-trading-higher-by-38-5419679)
- 2024-04-02 20:32 UTC [Market Chatter] [Centogene Receives Non-Compliance Notification Letter Dated March 27, 2024, From Nasdaq](https://www.quantisnow.com/insight/centogene-receives-non-compliance-notification-letter-dated-march-27-2024-from-5385229)
- 2024-04-02 20:30 UTC [CENTOGENE Receives Nasdaq Non-Compliance Notice](https://www.quantisnow.com/insight/centogene-receives-nasdaq-non-compliance-notice-5385161)
- 2024-04-02 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5385157)
- 2024-03-19 10:32 UTC [Market Chatter] [CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed](https://www.quantisnow.com/insight/centogene-extends-strategic-partnership-with-takeda-to-continue-providing-access-5352876)
- 2024-03-19 10:30 UTC [CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders](https://www.quantisnow.com/insight/centogene-extends-strategic-partnership-with-takeda-to-continue-providing-access-5352868)
- 2024-03-19 10:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Centogene N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-centogene-nv-5352866)
- 2024-02-29 22:07 UTC [Market Chatter] [CENTOGENE Collaborates On Research Published In Science Showing Immunopathological Landscape Of Human Pre-TCRα Deficiency](https://www.quantisnow.com/insight/centogene-collaborates-on-research-published-in-science-showing-immunopathological-landscape-5306615)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CNTG
- Earnings history: https://www.quantisnow.com/earnings/CNTG
- Dividend history: https://www.quantisnow.com/dividends/CNTG
- Insider transactions: https://www.quantisnow.com/insiders/CNTG
- Options chain: https://www.quantisnow.com/options/CNTG
- SEC 8-K filings only: https://www.quantisnow.com/company/CNTG/8-k
- RSS and alerts for CNTG: https://www.quantisnow.com/docs/rss-feeds.md